An integrated analysis of uterine carcinosarcomas uncovered a range of somatic mutations and shifts in transcription, methylation, and microRNA expression.
Ronald DePinho has resigned as president of the MD Anderson Cancer Center, Stat News reports.
Samples from metastatic melanoma patients treated sequentially with immunotherapies targeting CTLA4 and PD-1 pointed to response-related tumor features.
The multi-center precision medicine trial has matched approximately 700 patients to 24 treatment arms so far, but some arms appear to be falling short of their recruitment goal.
MD Anderson aims to rapidly collect clinical utility data to support decisions by relevant committees to broadly offer the test and to begin persuading payors to reimburse.
Guardant will help MD Anderson develop new assays and conduct clinical studies, and physicians will be able to order the company's test through an EMR system.
Researchers found that telomeres were shorter in tumors than in normal tissues and longer in sarcomas and gliomas than in other cancers.
MD Anderson Cancer Center is suing NantHealth's Patrick Soon-Shiong over 'moonshot' trademark, the Cancer Letter reports.
The planned instrument will help provide spatial information on both protein and RNA in tumor samples and will be powered by nCounter technology.
Researcher Gordon Mills said assays based on his lab's Cancer Proteome Atlas project could be used to guide patient treatment within the next 18 months.
Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.
Some science companies will be taking part in next month's March for Science, Fortune reports.
In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.
Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.